SCHEMBL5457643

SCHEMBL5457643

O=CNc1ccc(O)c(O)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.47
KDM4E B2RXH2 1/20 0.46
PTGS2 P35354 1/20 0.46
RAB9A P51151 1/20 0.46
ALDH1A1 P00352 1/20 0.44
KDM5A P29375 2/20 0.44
ARG1 P05089 1/20 0.44
TOP1 P11387 1/20 0.44
SNCA P37840 1/20 0.42
XDH P47989 2/20 0.41
ERCC1 P07992 1/20 0.40
ERCC4 Q92889 1/20 0.40
LCK P06239 1/20 0.39
ALOX15 P16050 2/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
PKLR P30613 1/20 0.39
APP P05067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7745183 0.83 KDM5A (0.59) EGFRKDM4ERAB9AALDH1A1KDM5A
SCHEMBL6991764 0.81 ALDH1A1 (0.47) ALDH1A1KDM5A
SCHEMBL13704093 0.81 KDM5A (0.41) EGFRKDM4ERAB9AALDH1A1KDM5A
SCHEMBL12635347 0.81 ALDH1A1 (0.40) EGFRKDM4ERAB9AALDH1A1KDM5A
SCHEMBL28009999 0.81 ALDH1A1 (0.49) EGFRRAB9AALDH1A1
SCHEMBL7745818 0.81 ALOX15 (0.45) KDM4ERAB9AALDH1A1KDM5ASNCA
SCHEMBL5462851 0.81 TP53 (0.45) KDM4ERAB9AALDH1A1KDM5AALOX15
SCHEMBL31008437 0.78 CA1 (0.52) EGFRKDM4EPTGS2ALDH1A1KDM5A
SCHEMBL7635128 0.78 KMT2A (0.56) KDM4ERAB9AALDH1A1KDM5A
SCHEMBL10763246 0.78 CA1 (0.52) EGFRKDM4EPTGS2ALDH1A1KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903072-A Dopa compound and preparation method and application thereof 深圳市松柏科工股份有限公司 2024-04-19 CN disclosed
EP-3007214-A1 COMPOSITION FOR FORMING GATE INSULATING FILM, ORGANIC THIN FILM TRANSISTOR, ELECTRONIC PAPER, AND DISPLAY DEVICE Fujifilm Corporation (JP) 2016-04-13 EP disclosed
EP-3001472-A1 ORGANIC SEMICONDUCTOR COMPOSITION, ORGANIC THIN-FILM TRANSISTOR, ELECTRONIC PAPER, AND DISPLAY DEVICE Fujifilm Corporation (JP) 2016-03-30 EP disclosed
EP-2014285-A1 NPYY5 antagonists Shionogi&Co., Ltd. (JP) 2009-01-14 EP disclosed
WO-2008130569-A1 NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2008-10-30 WO disclosed
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 EGFR 2482/4885KDM4E 3789/4885PTGS2 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.